Affiliations: [a] Institut National de la Santé et de la Recherche Médicale U788, Stéroïdes et Systèmes Nerveux, Le Kremlin-Bicêtre Cedex, France | [b] Laboratoire de Neuropathologie Escourolle, Hôpital de La Salpêtrière, AP-HP, Paris, France
Correspondence:
[*]
Correspondence to: Pr. Etienne Emile Baulieu, Institut National de la Santé et de la Recherche Médicale U788, Stéroïdes et Systèmes Nerveux, Le Kremlin-Bicêtre Cedex, France. Tel.: +331 49 59 18 82; Fax: +331 49 59 92 03; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Human neurodegenerative diseases characterized by abnormal intraneuronal inclusions of the tau protein, or “tauopathies”, include Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy, corticobasal degeneration as well as fronto-temporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). Several abnormalities of tau may contribute to the pathological processes, yet the mechanisms involved in tau cellular toxicity remain unclear. Previously, we demonstrated an interaction between various isoforms of tau and the immunophilin FKBP52 (FK506-Binding Protein), suggesting a direct involvement of FKBP52 in tau function. Here we analyze the expression of FKBP52 in human brains of patients with different tauopathies, including AD. Immunohistofluorescence studies carried out on cerebral cortex in different tauopathies reveal that FKBP52 is not sequestered by filamentous tau inclusions while FKBP52 is colocalized with tau in the control case brains. We found that FKBP52 expression level is abnormally low in frontal cortex of AD and FTDP-17 brains, as compared to controls, despite no alteration in the FKBP52 mRNA expression level. The possible involvement of FKBP52 in pathological tau expression/function is discussed.
